Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase
Source: SeekingAlpha
2026-03-03 07:30:56 ET
Thesis
Read the full article on Seeking Alpha
For further details see:
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase
Kymera Therapeutics Inc.
NASDAQ: KYMR
KYMR Trading
1.95% G/L:
$83.08 Last:
69,400 Volume:
$82.85 Open:
KYMR Latest News
February 26, 2026 07:00:00 am
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
February 24, 2026 07:00:00 am
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
KYMR Stock Data
$6,259,529,627
60,213,376
0.01%
74
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
